Title

Pediatric Survivorship: Considerations Following CAR T-Cell Therapy.

Authors

Colleen Callahan, Children's Hospital of Philadelphia, Philadelphia, PAFollow
Amy Barry, Children's Hospital of Philadelphia, Philadelphia, PA
Stephanie Fooks-Parker, Children's Hospital of Philadelphia, Philadelphia, PAFollow
Laura Smith, Children's Hospital of Philadelphia, Philadelphia, PA
Diane Baniewicz, Children's Hospital of Philadelphia, Philadelphia, PAFollow
Wendy Hobbie, Children's Hospital of Philadelphia, Philadelphia, PAFollow

Publication Title

Clinical journal of oncology nursing

Document Type

Article

PubMed ID

30880817

Abstract

BACKGROUND: This article presents an overview of pediatric relapsed and refractory acute lymphoblastic leukemia (ALL) and chimeric antigen receptor (CAR) T-cell therapy in pediatric patients.

OBJECTIVES: Acute and chronic post-CAR T-cell effects and considerations are discussed, along with survivorship considerations.

METHODS: A case study illustrates the identification and management of physiologic and psychosocial sequelae.

FINDINGS: B-cell aplasia, hypogammaglobulinemia, infections, and cumulative effects of CAR T-cell therapy and other treatments are a concern in the pediatric population. Unique to pediatric and young adult survivors of childbearing potential are implications for post-treatment fertility. Financial toxicities and psychosocial needs require a family-centered approach to interventions that address the impact of CAR T-cell therapy not only on the patient, but also on caregivers and siblings.

Keywords

Humans, Immunotherapy, Adoptive, Pediatrics, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Survival Rate

DOI

10.1188/19.CJON.S1.35-41

Publication Date

4-1-2019

Citation

Callahan, C., Barry, A., Fooks-Parker, S., Smith, L., Baniewicz, D., & Hobbie, W. (2019). Pediatric Survivorship: Considerations Following CAR T-Cell Therapy.. Clinical journal of oncology nursing, 23 (2), 35-41. https://doi.org/10.1188/19.CJON.S1.35-41